Gail L. Wrigley

AstraZeneca (United Kingdom) — United Kingdom

Medicine · Health Sciences

12h-index1.4kcitations47works3.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(11), Crystallization and Solubility Studies(8), X-ray Diffraction in Crystallography(8), HER2/EGFR in Cancer Research(7), Chemical Synthesis and Analysis(7)

Publications47 total

Solvent Sustainability in Drug Discovery: Where Are We Now, and How Can We Improve?
Journal of Medicinal Chemistry·2025Open Access
Design, Modular Synthesis and Screening of 58 Shape-Diverse 3-D Fragments
2025Open Access
Design, modular synthesis and screening of 58 shape-diverse 3-D fragments
Chemical Science·2025Open Access
Accelerated Discovery of Carbamate Cbl-b Inhibitors Using Generative AI Models and Structure-Based Drug Design
Journal of Medicinal Chemistry·2024· 8 citedOpen Access
Discovery, Optimization, and Biological Evaluation of Arylpyridones as Cbl-b Inhibitors
Journal of Medicinal Chemistry·2024· 10 citedOpen Access
Discovery of a Novel Benzodiazepine Series of Cbl-b Inhibitors for the Enhancement of Antitumor Immunity
ACS Medicinal Chemistry Letters·2023· 12 citedOpen Access
Modular, automated synthesis of spirocyclic tetrahydronaphthyridines from primary alkylamines
Communications Chemistry·2023· 4 citedOpen Access
Modular, Automated Synthesis of Spirocyclic Tetrahydronaphthyridines from Primary Alkylamines
Research Square (Research Square)·2023· 1 citedOpen Access
Correction to “Discovery of a Thiadiazole–Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models”
Journal of Medicinal Chemistry·2023
Supplementary Data from Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs
2023Open Access
Supplementary Data from Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs
2023Open Access
Data from Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs
2023Open Access
Figure S1 from Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs
2023Open Access
Data from Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs
2023Open Access
Figure S1 from Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs
2023Open Access
Isotopic Radiolabeling of Crizotinib with Fluorine-18 for In Vivo Pet Imaging
Pharmaceuticals·2022· 2 citedOpen Access
Exploration of piperidine 3D fragment chemical space: synthesis and 3D shape analysis of fragments derived from 20 regio- and diastereoisomers of methyl substituted pipecolinates
RSC Medicinal Chemistry·2022· 8 citedOpen Access
CCDC 2093033: Experimental Crystal Structure Determination
The Cambridge Structural Database·2021Open Access
Photocatalytic Hydroaminoalkylation of Styrenes with Unprotected Primary Alkylamines
Journal of the American Chemical Society·2021· 76 citedOpen Access
Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance
Journal of Medicinal Chemistry·2021· 31 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

M. Raymond V. Finlay(17), Nicola Colclough(10), Darren A.E. Cross(10), Richard A. Ward(10), Simon Jones(10), James D. Firth(10), Roderick E. Hubbard(10), David C. Blakemore(10), Claudia De Fusco(10), Stephen D. Roughley(10), Lewis R. Vidler(10), Maria Ann Whatton(10), Alison J.‐A. Woolford(10), Thomas D. Downes(9), Hanna F. Klein(9), Peter O’Brien(9), Peter Johnström(8), Magnus Schou(8), Annika Janefeldt(8), Mikhail Kondrashov(8)